Resource

Letter to CSPI et al. from Dr. Peter Marks

Director of FDA's CBER Responds to CSPI Letter

ShareThis

Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, responded to a CSPI-organized letter from 400 prominent experts in vaccine technology, epidemiology, virology, and other public health fields urging that the FDA not make a COVID-19 vaccine widely available until Phase 3 clinical trials are complete.

Topic: